|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2010-1-1
|
|
pubmed:abstractText |
In a previous phase I clinical trial of dietary methionine (MET) restriction with cystemustine treatment for melanoma or glioma, we determined the optimal MET-free diet duration to be 1 day. On this basis, a phase II clinical trial was initiated to evaluate safety and efficacy of this combination.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1791-7530
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
29
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
5235-40
|
|
pubmed:meshHeading |
pubmed-meshheading:20044642-Adult,
pubmed-meshheading:20044642-Aged,
pubmed-meshheading:20044642-Antineoplastic Agents,
pubmed-meshheading:20044642-Brain Neoplasms,
pubmed-meshheading:20044642-Choroid Neoplasms,
pubmed-meshheading:20044642-Combined Modality Therapy,
pubmed-meshheading:20044642-Diet,
pubmed-meshheading:20044642-Female,
pubmed-meshheading:20044642-Glioma,
pubmed-meshheading:20044642-Humans,
pubmed-meshheading:20044642-Male,
pubmed-meshheading:20044642-Maximum Tolerated Dose,
pubmed-meshheading:20044642-Melanoma,
pubmed-meshheading:20044642-Methionine,
pubmed-meshheading:20044642-Middle Aged,
pubmed-meshheading:20044642-Neoplasm Staging,
pubmed-meshheading:20044642-Nitrosourea Compounds,
pubmed-meshheading:20044642-Nutritional Status,
pubmed-meshheading:20044642-Prognosis,
pubmed-meshheading:20044642-Survival Rate,
pubmed-meshheading:20044642-Treatment Outcome
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Phase II trial of the association of a methionine-free diet with cystemustine therapy in melanoma and glioma.
|
|
pubmed:affiliation |
Centre Jean Perrin, 58 rue Montalembert, BP 392, 63011 Clermont-Ferrand cedex 1, France. Recherche.CLINIQUE@cjp.fr
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial, Phase II
|
